Nuvalent, Inc. (NUVL)

67.52 -0.02 (-0.03%) At close: 04:00PM EDT

Nuvalent, Inc.

One Broadway
14th Floor
Cambridge, MA 02142
United States
857 357 7000
https://www.nuvalent.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 92

Key executives

Name	Title	Pay	Exercised	Year born
Dr. James R. Porter Ph.D.	CEO, President & Director	1.05M	N/A	1976
Prof. Matthew D. Shair Ph.D.	Founder, Head of Scientific Advisory Board & Director	239k	N/A	1969
Dr. Christopher D. Turner M.D.	Chief Medical Officer	750.97k	N/A	1969
Dr. Benjamin Lane Ph.D.	Senior Vice President of Technical Operations	N/A	N/A	N/A
Ms. Deborah Ann Miller J.D., Ph.D.	Chief Legal Officer & Secretary	595.96k	N/A	1976
Mr. Matthew Metivier	Senior Vice President of Human Resources	N/A	N/A	N/A
Ms. Darlene Noci	Chief Development Officer	N/A	N/A	1978
Mr. Henry Pelish Ph.D.	Senior Vice President of Drug Discovery	N/A	N/A	N/A
Mr. John Soglia Ph.D.	Senior Vice President of Translational Development	N/A	N/A	N/A
Ms. Perrin Wilson B.S., Ph.D.	Senior Vice President of Business Development & Strategy	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Nuvalent, Inc.’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.